Inc.
A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs
The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.
Rachel Suleymanov
No AI assistance disclosed

---
Rachel Suleymanov · Inc.
Source & Credit
Reporting and photography credited as noted above. Originally published by Inc..
Members only
Checking your membership…